Key facts
- Macrobiome Therapeutics’s last known valuation is $870K (Aug 2023).
- It has raised $200K; the latest was Seed Round in Sep 2025.
- Notable investors include Main Sequence Ventures, Brisbane Economic Development Agency, CRCNA, Department of Industry, Science and Resources — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Macrobiome Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Macrobiome Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Macrobiome Therapeutics
Operator of a drug development firm intended to develop biologics for treating disorders that result from a dysfunctional immune system. The company aims to harness the therapeutic potential of hookworms and other parasitic helminths to develop drugs for the treatment of autoimmune and metabolic diseases such as inflammatory bowel disease (IBD) and type two diabetes (T2D), enabling clinicians to get access to novel therapeutics that will inhibit chronic debilitating diseases with limited efficacious treatment options.
- Sector
- Healthcare
- HQ
- Cairns, Australia
- Founded
- 2020
- Website
- macrobiometherapeutics.com/
- Ownership
- Privately Held (backing)
Macrobiome Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Macrobiome Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Macrobiome Therapeutics in its N-PORT filings yet. We sweep new filings monthly.